ation with incident CKD, many reports have provided mixed results in terms of this association [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Data from some studies suggest that there is no such independent association between smoking and incident CKD [19, 22] , whereas other data suggest that smoking is an independent risk factor for this disease [5, 7, 13] . To the best of our knowledge, two systematic reviews have evaluated cigarette smoking as a risk factor for incident CKD [23, 24] . The most recent review explored the development of CKD in healthy populations [24] , which included 10 cohort and 18 cross-sectional/case-control studies. Unfortunately, no quantitative assessment was performed in that study. Since that report was published, additional prospective cohort studies on this issue have emerged [15] [16] [17] [18] [19] [20] [21] [22] . In addition, cross-sectional and case-control studies are more subject to recall or selection bias than cohort studies. Therefore, to better characterize the association between smoking status and incident CKD, we conducted a comprehensive meta-analysis of prospective cohort studies. This meta-analysis followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines [25] .
M A T E R I A L S A N D M E T H O D S

Literature search
Two of the authors (X.J. and H.L.Q.) searched for Englishand non-English-language publications on Embase (http:// www.embase.com/ last accessed) and MEDLINE (PubMed, http://www.ncbi.nlm.nih.gov/pubmed/ last accessed) from inception through 31 May 2016. The search terms included the following keywords: (i) smoking OR cigarette OR tobacco OR nicotine (ii) chronic kidney disease OR CKD OR creatinine OR kidney injury OR end-stage renal disease OR glomerular filtration rate OR renal failure OR albuminuria OR microalbuminuria OR macroalbuminuria OR proteinuria and (iii) cohort OR prospective. To identify any additional relevant studies, a manual search of the references cited in the obtained literature was also performed. Eligibility and exclusion criteria were prespecified. Our search was limited to human studies.
Study selection
Studies were included according to the following criteria: (i) the design was based on a prospective cohort study in an adult (age !18 years) general population, (ii) the study provided risk estimates and their confidence intervals (CIs) to assess the association between smoking status and incident CKD and (iii) the studies adjusted for age, hypertension (or blood pressure) and diabetes (or blood glucose level). Animal studies, in vitro research, case reports, retrospective studies, ecological studies and reviews were considered ineligible. If multiple papers reported results from the same study, the most informative report was included; for example, reports with a larger number of cases and/or a longer duration of follow-up. Data on progression of CKD or renal function decline were not analysed. We did not consider the grey literature. Two studies [11, 22] were also included that primarily assessed the association between other predictors (urinary pH and serum uric acid, respectively) and the development of CKD. Furthermore, smoking was one of the many covariates adjusted for in the multivariable model. Two investigators (X.J. and H.L.Q.) independently reviewed all potentially relevant articles and disagreement was resolved by discussion between the investigators.
Data extraction and assessment of study quality
Two researchers (X.J. and H.L.Q.) independently extracted the following data from each publication: the lead author's last name, year of publication, study locations, participant characteristics, smoking category, the number and definition of outcomes, duration of follow-up and co-variables adjusted for in the analysis. From each study we extracted the risk estimates that reflected the greatest degree of control for potential confounders. If separate risk estimates for males and females were available in one study, we treated these as separate studies.
Study quality was assessed using the Newcastle-Ottawa quality assessment scale (NOS) [26] and a maximum of 9 points reflects the highest quality. A total score !7 was used to indicate high-quality studies.
Exposure and outcome measures
Some articles reported on ever-smoking use. Others reported on both former and current smoking use, so results on eversmoking use could be computed by combining the results for both users. Additionally, some studies only reported on current smokers. In such instances, current users were considered as ever-users.
Estimated glomerular filtration rate (eGFR) was computed using standardized serum creatinine according to the Modification of Diet in Renal Disease (MDRD) study equation [27] in most of the included studies [7, 9-11, 13 ,17, 18] . The following outcome measures were considered for inclusion: (i) CKD was defined as development of persistent (>3 months) eGFR <60 ml/min/1.73m 2 ; (ii) ESRD was defined as development of eGFR <15 ml/min/1.73m 2 or where RRT was commenced; (iii) proteinuria was defined as the following: microalbuminuria, 24-h albumin excretion rate or proteinuria on fresh morning urine dipstick and persistent >3 months [28] .
Statistical analysis
All statistical analyses were performed using STATA version 11.0 (StataCorp, College Station, TX, USA). We combined the study-specific risk estimates (with 95% CIs) using a random effects model, which accounts for heterogeneity among studies [29] . Significance was set at P ¼ 0.05.
In assessing heterogeneity among studies, we used the Cochran's Q and I 2 statistics. The I 2 statistics are the percentage of total variation across studies due to heterogeneity rather than chance. Results were defined as being significantly heterogeneous for P-values <0.10 or I 2 >50% [30] . We explored the origin of heterogeneity by conducting subgroup analyses according to study characteristics such as country of origin, gender, baseline age, number of cases, duration of follow-up and confounders [these included alcohol use, body mass index (BMI), history of CVD and dyslipidaemia]. Heterogeneity was also evaluated by random effects meta-regression analysis, which looked at the effect of potential covariates on the
We conducted a sensitivity analysis to estimate the influence of each individual study on the summary results by repeating the random effects meta-analysis after omitting one study at a time. Sensitivity analysis was also performed by combining studies with adjustments for measurement of baseline kidney function. Publication bias was assessed by using funnel plots and Egger's regression asymmetry test [31] . P-values <0.10 were considered to be representative of statistically significant publication bias.
R E S U L T S
Search results and study characteristics Figure 1 shows the study selection process and results from the literature search. We identified 1838 articles from the PubMed database and 1856 articles from the Embase database. After exclusion of duplicates and papers that did not meet the inclusion criteria, 77 had potential value and were available as full-text articles. An additional 16 articles were included from the reference reviews. In reviewing these 93 articles, 75 were subsequently excluded from the meta-analysis for various reasons ( Figure 1 ). Therefore, a total of 18 prospective cohort studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] were included in the meta-analysis (Table 1) .
These 18 studies were published between 2003 and 2015 and comprised a total of 2 413 844 participants (ranging from 1811 to 1 574 749). After a median duration of follow-up of 10 years (ranging from 4 to 18.5 years), 65 064 incident CKD cases and 5747 proteinuria cases (ranging from 77 to 41 119) were identified. The continents or countries where the studies were conducted were the USA (n ¼ 10), Europe (n ¼ 3) and Asia (n ¼ 5). All studies made adjustments for age, gender, hypertension and history of DM. More than half of the studies made adjustments for BMI, alcohol consumption and dyslipidaemia. According to the NOS, all studies were of high quality (NOS >6).
Smoking status and incident CKD
Risk estimates for incident CKD according to smoking status were reported by 15 cohort studies [5-7, 9-13, 15-20, 22] . Compared with never-smokers, ever-smokers were associated with an elevated risk of CKD development [summary relative risk (SRR) 1.27 (95% CI 1.19-1.35)] (Figure 2A ). In all, eight studies [6, 9, 10, 12, 13, 15, 17, 18] presented results on former smoking, with an SRR of 1.15 (95% CI, 1.08-1.23; Figure 2B ). A total of 11 studies [6, 9-13, 15, 17, 18] presented results on current smoking, with an SRR of 1.34 (95% CI, 1.23-1.47; Figure 2C ). Current smokers had a significantly higher risk of CKD development than former smokers (P for difference <0.001). We found considerable heterogeneity among the studies for ever-smokers (I 2 ¼ 80.6%), former smokers (I 2 ¼ 61.1%) and current smokers (I 2 ¼ 83.7%).
Smoking status and incident ESRD
Risk estimates for the development of ESRD according to smoking status were reported by seven prospective cohort studies [5, 6, 12, 15, 16, 18, 20] . Compared with never-smokers, ever-smokers were associated with an elevated risk of ESRD development [SRR 1.51 (95% CI 1.24-1.84); Figure 3A ]. The SRRs 
were 1.44 (95% CI, 1.00-2.09; Figure 3B ) for former smokers and 1.91 (95% CI, 1.39-2.64; Figure 3C ) for current smokers. Considerable heterogeneity among the studies for ever-smokers (I 2 ¼ 74.2%), former smokers (I 2 ¼ 62.8%) and current smokers (I 2 ¼ 64.0%) was observed.
Subgroup, sensitivity and meta-regression analyses Table 2 shows the results of subgroup analyses for the association between ever-smokers and incident CKD. Stratified analyses by study location led to statistically significant SRRs of 1.50 (95% CI, 1.25-1.81) for studies from the USA, 1.24 (95% CI, 1.14-1.33) for studies from Europe and 1.17 (95% CI, 1.03-1.32) for studies from Asia. In stratified analysis by gender, a significant association between ever-smoking and incident CKD was observed in both men [SRR 1.28 (95% CI 1.13-1. In sensitivity analyses, we recalculated the overall homogeneity and effect size by excluding one study at a time. The SRRs ranged from a low of 1.25 (95% CI 1.18-1.33) to a high of 1.33 (95% CI 1.23-1.43) when the studies by Tohidi et al. [17] and Yamagata et al. [10] were omitted, respectively (data not shown). Sensitivity analysis by combining studies with adjustments for measurement of baseline kidney function resulted in a somewhat stronger risk association for ever-smokers [SRR 1.47 (95% CI 1.25-1.72)]. Meta-regression analysis showed that only the duration of follow-up was a significant variable for the association of ever-smoking-incident CKD, which might account for 33.8% of the heterogeneity.
Dose-response relationship
We further examined the dose-response relationship of smoking and incident CKD. In a 13.3-year follow-up study of 63 257 Chinese adult participants, Jin et al. [18] demonstrated a slightly increased renal failure risk in men (but not in women) who smoked for a longer duration [hazard ratio (HR) among smokers for >40 years ¼ 1.56 (95% CI 1.13-2.14)] [18] . Stengel et al. [6] found an increased risk of developing ESRD in both males and females who smoked >20 cigarettes/day [relative risk (RR) 2.6 (95% CI 1.4-4.7)]. Similarly, the HUNT II study [15] of 65 589 Norwegian participants revealed an elevated risk of kidney failure as the cumulative amount of smoking (pack-years) increased (P for trend <0.001). 
| | | | | | | | | | | | | | | | | | | | | | | |
Smoking cessation and CKD
Only two prospective cohort studies [15, 18] reported data on smoking cessation and incident CKD, therefore we could not conduct a quantitative review for this topic. Jin et al. [18] reported that the risk of renal failure in men remained significantly enhanced even 1-9 years after cessation of smoking, although the HR decreased to 1.02 at !10 years after cessation. A similar pattern was observed in women, albeit with no significant association due to small female case numbers. Hallan et al. [15] reported that the risk significantly decreased as the years elapsed since smoking cessation increased among male former smokers (P for trend ¼ 0.005).
Publication bias
According to Egger's regression asymmetry test, we observed no evidence of publication bias for the association between smoking status and incident CKD (P ever-smoking ¼ 0.616, Figure 4A ; Figure 4B ; P current smoking ¼ 0.472, Figure 4C ).
Smoking status and incident proteinuria
Three prospective cohort studies [8, 14, 21] evaluated incident proteinuria according to smoking status. One study was from Korea [8] and the other two were from the USA [14, 21] . Compared with never-smokers, ever-smokers were not associated with a statistically increased risk of incident proteinuria [SRR 1.34 (95% CI 0.91-1.97); Figure 5 ].
D I S C U S S I O N
In this meta-analysis of prospective cohort studies, we found that cigarette smoking was associated with an elevated risk of incident CKD/ESRD in the adult general population. These associations were independent of well-established risk factors for CKD such as age, hypertension, DM and BMI. Smoking cessation significantly decreased the risk of incident CKD, although elevated CKD risk in those who stopped smoking persists for many years. In addition, smoking is not associated with incident albuminuria/proteinuria in the general adult population.
Cigarette smoking has been identified as one of the most significant risk factors for incident CKD in those with DM [32, 33] . Furthermore, prospective studies have reported that smoking is positively associated with the progression of CKD in diabetic nephropathy [33, 34] , IgA nephropathy [35] and idiopathic membranous nephropathy [36] . However, this relationship in the general population is less clear. The first prospective study examining this issue was published in 2000, which showed that cigarette smoking was associated with CKD as manifested by proteinuria and/or lowered GFR in generally healthy adults [37] . A subsequent prospective cohort of the Framingham Offspring Study defined the longitudinal relationship between smoking and incident albuminuria, independent of effects of DM [38] . However, some studies showed an even higher GFR in smokers than in non-smokers, especially those studies that were conducted in general healthy populations [39] .
Although the precise nature of the nephrotoxic effect of cigarette smoking is not well understood, various mechanisms have been indicated. First, smoking has chronic effects, including endothelial cell dysfunction (diminished nitric oxide availability and endothelial cell-dependent vasodilation and intimal cell hyperplasia), pro-inflammation, oxidative stress, glomerulosclerosis and tubular atrophy [40, 41] . In vivo studies have suggested that nicotine can promote mesangial cell proliferation and increase production of the extracellular matrix [42, 43] . Second, recent research [44] has found that cigarette smoke contains glycotoxins, which can rapidly induce advanced glycation end products (AGEPs) formation both in vivo and in vitro. AGEPs have been shown to increase vascular permeability [45] and promote pathological vascular changes of renal disease [46] . Third, smoking has been linked to insulin resistance in diabetic [47] and non-diabetic subjects [48, 49] . Observational studies have indicated that insulin resistance is an independent predictor of CKD [50, 51] and albuminuria [52] .
Interestingly, our meta-analysis identified the duration of follow-up as a modified factor for the association between smoking and incident CKD. An increased risk was stronger for studies with longer duration of follow-up than with shorter duration of follow-up (RR: ever-smoking 1.56 versus 1.19; current smoking 1.91 versus 1.24, respectively), suggesting that there are cumulative effects of cigarette smoking on incident CKD. [18] and Norwegian [15] adult participants, researchers demonstrated that the risk increased significantly as the cumulative amount of smoking (pack-years) increased.
In this meta-analysis, a greater risk was evident in current smokers than in former smokers (RR 1.34 versus 1.15; P for difference < 0.001), suggesting that cessation of smoking significantly decreased the risk of incident CKD, although there is an elevated risk of CKD in former smokers that persists for many years. Jin et al. [18] directly reported that the adjusted HR of kidney failure in men decreased to 1.02 at !10 years after cessation of smoking. Similarly, the HUNT II study found that the ESRD risk significantly decreased as the years elapsed since smoking cessation increased among male ex-smokers (P for trend ¼ 0.005) [15] . One of the mechanisms underlying the persistence of smoking-associated renal damage after smoking cessation may be related to smoking-induced changes in the epigenetics of blood platelets, which can persist for >10 years after smoking cessation [53, 54] .
The strengths of our study are as follows: (i) this metaanalysis is the first quantitative review to show a statistically significant association between cigarette smoking and incident CKD; (ii) we restricted our analysis to prospective cohort studies in the general population, which are less prone to recall or selection bias; (iii) all of the studies included in the meta- analysis evaluated the most important risk factors for CKD (age, hypertension and diabetes) and the majority of the studies adjusted for multiple important confounders including BMI, alcohol use, history of CVD and dyslipidaemia; and (iv) the summary risk estimate was stable and robust after comprehensive subgroup and sensitivity analyses.
As with any meta-analysis of observational studies, our study has limitations. First, misclassifications of exposure and outcome are likely to be present in the pooled results. In many studies, smoking status was self-reported at baseline and did not account for changes in smoking habits over the course of follow-up. In the present meta-analysis, CKD was defined by a single creatinine measure or disease/death registry in some studies, thus misclassification of CKD cannot be ruled out. In addition, smokers (active and former versus never-smokers) require more invasive cardiac testing or cardiac revascularization, therefore they may experience more contrast-induced acute kidney injury (AKI), one of the most important complications of cardiac catheterization [55] . In contrast to the previous viewpoints that survivors of AKI tend to do well and fully recover their renal function, AKI may increase the risk for CKD and ESRD [56, 57] . In addition, CKD is an important risk factor for the The second limitation is that it is possible that the observed relationship between cigarette smoking and incident CKD is due to unmeasured or residual confounding. Cigarette smoking is an established risk factor for CVD, the major cause of death in ESRD patients. In addition to well-established factors (e.g. advanced age, hypertension, DM and dyslipidaemia), those less established factors (e.g. anaemia, volume overload, mineral metabolism abnormalities and proteinuria) might provide an explanation for the high prevalence of CVD in CKD cases [59] . However, adjustments for history of CVD did not alter the aforementioned risk association in our subanalyses. Smokers tend to be associated with heavy alcohol consumption [60] , which has been linked to decreased risk of incident CKD [61] . However, an increased association between cigarette smoking and incident CKD persisted when we restricted the meta-analysis of studies that adjusted for alcohol consumption. Furthermore, smokers tend to be thinner on average than non-smokers [62] . The majority of studies included in our meta-analysis adjusted for BMI or obesity. When performing a subgroup meta-analysis by alcohol use or BMI, we obtained similar risk estimates. These results suggest that the associations between cigarette smoking and incident CKD are not explained by these confounders. However, a meta-analysis is unable to solve problems with confounding factors that could be inherent in the included studies.
Third, high heterogeneity across studies was present. The definition, classification of smokers and the methods used for quantifying tobacco exposure are different, which may yield varied results with regard to the strength of the association with incident CKD. In, addition, the methods used to define CKD are different in the included studies and CKD is a complex aetiology where pathophysiological disease manifests due to combined effects of genes and environmental factors. Thus, the methods used to define CKD, other genetic and environment variables, as well as their possible interactions may be potential contributors to the observed heterogeneity. Additionally, quality scoring adds subjective bias to the results, which can prevent the recognition of key sources of heterogeneity. Considerable heterogeneity could make the results less robust. Nevertheless, our subgroup and meta-regression analyses demonstrated that the risk estimate was robust across various quality components. In addition, based on meta-regression analyses, the variable of duration of follow-up was one of the significant factors for this association.
Fourth, our analysis is limited to data from relatively few countries (USA, England, Norway, Austria, Japan, Iran, Korea and Singapore). Thus, we could not assess whether associations differ by geographic location or by cultural and ethnic differences across populations. Assessment of dose-response is considered to be a major criterion for determination of the causality of an association. Because of the absence or differences in the categorization of exposure data in the individual studies, we could not perform a quantitative review of the risk relationship.
Finally, despite no suggestion of major publication bias in formal assessments, publication bias is a concern since small studies with null results (the grey literature) tend to be unpublished. This bias may have led to an overestimation of the true association.
In conclusion, results from our meta-analysis of cohort studies clearly demonstrate an adverse impact of smoking on incident CKD in adult patients from the general population. Whether smoking cessation can decrease the risk of incident CKD or not warrants further investigation.
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